ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL502835
CHEMBL502835
Compound Name NINTEDANIB
ChEMBL Synonyms OFEV | NINTEDANIB | Vargatef | BIBF 1120 | NINTEDANIB ESYLATE | BIBF-1120
Max Phase 4 (Approved)
Trade Names Vargatef | OFEV
Molecular Formula C31H33N5O4

Additional synonyms for CHEMBL502835 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN4CCN(C)CC4)/c5cccc ...
Download SMILES
Standard InChI InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24 ...
Download InChI
Standard InChI Key XZXHXSATPCNXJR-ZIADKAODSA-N

Sources

  • British National Formulary
  • Clinical Candidates
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL502835

Molecule Features

CHEMBL502835 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:Y Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Fibroblast growth factor receptor inhibitor Fibroblast growth factor receptor FDA
Platelet-derived growth factor receptor inhibitor Platelet-derived growth factor receptor FDA
Vascular endothelial growth factor receptor inhibitor Vascular endothelial growth factor receptor FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
GliosarcomaD018316EFO:1001465gliosarcoma2ClinicalTrials
Lung Diseases, InterstitialD017563EFO:0004244interstitial lung disease3ClinicalTrials
MesotheliomaD008654EFO:0000770malignant pleural mesothelioma3ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma1ClinicalTrials
SarcomaD012509EFO:0000691sarcoma2ClinicalTrials
Small Cell Lung CarcinomaD055752EFO:0000702small cell lung carcinoma2ClinicalTrials
OligodendrogliomaD009837EFO:0002501anaplastic oligodendroglioma2ClinicalTrials
Ovarian NeoplasmsD010051EFO:0003893ovarian neoplasm1ClinicalTrials
AstrocytomaD001254EFO:0002499anaplastic astrocytoma2ClinicalTrials
Endometrial NeoplasmsD016889EFO:0004230endometrial neoplasm2ClinicalTrials
GlioblastomaD005909EFO:0000519glioblastoma multiforme1ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma2ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma2ClinicalTrials
Colorectal NeoplasmsD015179EFO:0004142colorectal neoplasm3ClinicalTrials
Genital Neoplasms, FemaleD005833EFO:1001331Genital neoplasm, female1ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000681renal cell carcinoma2ClinicalTrials
Head and Neck NeoplasmsD006258EFO:0004284upper aerodigestive tract neoplasm2ClinicalTrials
Uterine Cervical NeoplasmsD002583EFO:0001416cervical adenocarcinoma2ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000708squamous cell lung carcinoma2ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma3ClinicalTrials
Idiopathic Pulmonary FibrosisD054990EFO:0000768idiopathic pulmonary fibrosis4ClinicalTrials
DailyMed
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia1ClinicalTrials
MelanomaD008545EFO:0000389cutaneous melanoma1ClinicalTrials
MesotheliomaD008654EFO:0000588mesothelioma3ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials
Scleroderma, SystemicD012595EFO:0000717systemic scleroderma3ClinicalTrials
Thyroid NeoplasmsD013964EFO:0002892thyroid carcinoma2ClinicalTrials
LymphangioleiomyomatosisD018192Orphanet:538Lymphangioleiomyomatosis2ClinicalTrials
Ovarian NeoplasmsD010051EFO:0001075ovarian carcinoma1ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma2ClinicalTrials
Appendiceal NeoplasmsD001063EFO:0003880appendiceal neoplasm2ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma3ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma1ClinicalTrials
Stomach NeoplasmsD013274EFO:0000503gastric adenocarcinoma2ClinicalTrials

Clinical Data

ClinicalTrials.gov NINTEDANIB
The Cochrane Collaboration NINTEDANIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL502835. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL2007 Platelet-derived growth factor receptor alpha Homo sapiens 1.000
CHEMBL1955 Vascular endothelial growth factor receptor 3 Homo sapiens 1.000
CHEMBL1868 Vascular endothelial growth factor receptor 1 Homo sapiens 0.998
CHEMBL3650 Fibroblast growth factor receptor 1 Homo sapiens 0.994
CHEMBL2026 Beta-lactamase AmpC Escherichia coli K-12 0.981
CHEMBL1287622 Lethal(3)malignant brain tumor-like protein 1 Homo sapiens 0.956
CHEMBL3935 Serine/threonine-protein kinase Aurora-C Homo sapiens 0.859
CHEMBL2392 DNA polymerase beta Homo sapiens 0.828
CHEMBL4439 TGF-beta receptor type I Homo sapiens 0.777
CHEMBL5514 Huntingtin Homo sapiens 0.769
CHEMBL1293224 Microtubule-associated protein tau Homo sapiens 0.619
CHEMBL3577 Aldehyde dehydrogenase 1A1 Homo sapiens 0.597
CHEMBL6110 Thioredoxin glutathione reductase Schistosoma mansoni 0.504
CHEMBL4096 Cellular tumor antigen p53 Homo sapiens 0.373
CHEMBL2608 Lysosomal alpha-glucosidase Homo sapiens 0.267



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL2007 Platelet-derived growth factor receptor alpha Homo sapiens 1.000
CHEMBL1955 Vascular endothelial growth factor receptor 3 Homo sapiens 1.000
CHEMBL2026 Beta-lactamase AmpC Escherichia coli K-12 0.937
CHEMBL3650 Fibroblast growth factor receptor 1 Homo sapiens 0.936
CHEMBL1868 Vascular endothelial growth factor receptor 1 Homo sapiens 0.935
CHEMBL1293299 Histone-lysine N-methyltransferase MLL Homo sapiens 0.856
CHEMBL4439 TGF-beta receptor type I Homo sapiens 0.644
CHEMBL5332 Mitogen-activated protein kinase 7 Homo sapiens 0.629
CHEMBL3577 Aldehyde dehydrogenase 1A1 Homo sapiens 0.624
CHEMBL1287622 Lethal(3)malignant brain tumor-like protein 1 Homo sapiens 0.550
CHEMBL6110 Thioredoxin glutathione reductase Schistosoma mansoni 0.471
CHEMBL1963 Thyroid stimulating hormone receptor Homo sapiens 0.249
CHEMBL2608 Lysosomal alpha-glucosidase Homo sapiens 0.210

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
539.6 539.2533 3.62 7 94.22 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 2 1 9 2 1


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
11.06 7.43 2.38 2.05 3 40 0.35

Structural Alerts

There are 4 structural alerts for CHEMBL502835. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE31 - nintedanib

ChemSpider ChemSpider:XZXHXSATPCNXJR-ZIADKAODSA-N
DailyMed nintedanib esylate

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL502835



BindingDB 50026612
ChEBI 85164
ChemicalBook CB92467147 CB72510401
DrugBank DB09079
DrugCentral 4903
FDA SRS G6HRD2P839
Guide to Pharmacology 5936
MolPort MolPort-009-679-380
Nikkaji J2.815.614F
PDBe XIN
PubChem 9809715
PubChem: Drugs of the Future 99431587
PubChem: Thomson Pharma 14836969
Selleck BIBF1120
SureChEMBL SCHEMBL431006
ZINC ZINC000100014909

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/XZXHXSATPCNXJR-ZIADKAODSA-N spacer
spacer